APS-03118 is under clinical development by Applied Pharmaceutical Science and currently in Phase II for Medullary Thyroid Cancer. According to GlobalData, Phase II drugs for Medullary Thyroid Cancer have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APS-03118’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APS-03118 overview
APS-03118 is under development for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other advanced solid tumors caused by rearranged during transfection (RET) gene alterations. The drug candidate is a selective RET kinase inhibitor.
Applied Pharmaceutical Science overview
Applied Pharmaceutical Science (APS) is a biopharmaceutical company focused on cancer precision therapy and tumor-driven gene drug development. APS is headquartered in Beijing, China.
For a complete picture of APS-03118’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.